Shire PLC (SHP) Receives Hold Rating from Liberum Capital
Liberum Capital reiterated their hold rating on shares of Shire PLC (LON:SHP) in a research report sent to investors on Monday morning. They currently have a GBX 4,900 ($63.47) price objective on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on SHP. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a report on Monday, March 13th. Goldman Sachs Group, Inc. (The) reaffirmed a conviction-buy rating and issued a GBX 6,800 ($88.08) price objective on shares of Shire PLC in a report on Thursday, March 16th. J P Morgan Chase & Co reissued an overweight rating and set a GBX 6,000 ($77.72) target price on shares of Shire PLC in a research note on Tuesday, March 21st. Deutsche Bank AG reissued a buy rating and set a GBX 6,300 ($81.61) target price on shares of Shire PLC in a research note on Wednesday, March 22nd. Finally, BNP Paribas reissued an outperform rating and set a GBX 5,900 ($76.42) target price on shares of Shire PLC in a research note on Wednesday, March 22nd. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Shire PLC currently has a consensus rating of Buy and a consensus target price of GBX 6,092.27 ($78.92).
Shares of Shire PLC (LON SHP) opened at 4175.00 on Monday. The stock has a 50 day moving average of GBX 4,526.50 and a 200 day moving average of GBX 4,615.89. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The stock’s market cap is GBX 37.75 billion.
In other Shire PLC news, insider Dominic Blakemore acquired 152 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were purchased at an average price of GBX 4,255 ($55.12) per share, with a total value of £6,467.60 ($8,377.72).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.